Seelos Therapeutics Inc (SEEL)

[Dimitrios George]

Well Biggie daddy, a value of $8 per share (apparently picked out of thin air) based on an assumed successful PIII is still different than seeing that value reflected early on in the share price. Phase IIIs are never a slam dunk as you know.

While an FDA go ahead to conduct a PIII would be good news, and hopefully that would get some good press, a much better story would be announcement of a "Pfizer" teaming up with Apricus to conduct the PIII and market Femprox if approved. That removes the issue of funding the PIII. And that would get a bump in the share price.